AnimAb
0747.674.614 · rovalta.com · 20/09/2026
ACTIVE
AnimAb
Financial year 2025 · closed on 31/12/2025
Net result
-5,3 M €
-39.0% YoY
Gross margin
28,6 k €
-95.5% YoY
Equity
2,8 M €
-32.1% YoY
Workforce
5,6 ETP
+19.1% YoY
Overview
What does AnimAb do?
AnimAb is a Private limited company incorporated in 2020. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Gent. It employs on average 5,6 ETP workers (FTE).
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0747.674.614
Incorporation
27/05/2020
Legal form
Private limited company
Registered office
Technologiepark-Zwijnaarde 94
9052 Gent · FlandreSee on map
9052 Gent · FlandreSee on map
Contributed capital
18 099 999,38 €
Latest accounts
31/12/2025
Average workforce
5,6 ETP
Activities (NACE)
21201Manufacture of pharmaceutical preparations· main21201Manufacture of pharmaceutical preparations72109Research and experimental development on natural sciences and engineering72190Other research and experimental development on natural sciences and engineering74909Other professional, scientific and technical activities n.e.c.74999Other professional, scientific and technical activities n.e.c.
Joint committees (2)
- 20700
- 207000
Signals
Solid equityGood liquidityHealthy social debts
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 5 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 28,6 k € | -95.5% | 633,8 k € | +65.0% | 384,2 k € | -23.7% | 503,3 k € | +192% | 172,2 k € |
| EBITDA | -540,9 k € | -416% | 171,1 k € | +488% | 29,1 k € | -85.5% | 200,5 k € | +246% | -137,7 k € |
| Operating result | -5,5 M € | -38.4% | -4,0 M € | -44.8% | -2,7 M € | -62.7% | -1,7 M € | +16.1% | -2,0 M € |
| Net result | -5,3 M € | -39.0% | -3,8 M € | -45.4% | -2,6 M € | -61.1% | -1,6 M € | +17.3% | -2,0 M € |
| Balance sheet | |||||||||
| Equity | 2,8 M € | -32.1% | 4,1 M € | +10.5% | 3,7 M € | -41.6% | 6,3 M € | +115% | 2,9 M € |
| Total assets | 3,5 M € | -24.5% | 4,6 M € | +11.4% | 4,1 M € | -38.2% | 6,7 M € | +86.5% | 3,6 M € |
| Cash | 1,8 M € | -47.0% | 3,4 M € | +6.7% | 3,2 M € | -40.5% | 5,4 M € | +185% | 1,9 M € |
| Debts | 708,9 k € | +33.9% | 529,3 k € | +19.2% | 444,0 k € | +20.6% | 368,1 k € | +197% | 124,1 k € |
| Other | |||||||||
| Workforce | 5,6 ETP | +19.1% | 4,7 ETP | +2.2% | 4,6 ETP | – | 2,8 ETP | ||
Estimate
Indicative valuation
As an indication, this company is worth
between 2,5 M€ and 5 M€
See the valuationGovernance
Board of directors
Seen on filing of 31/12/2025 · 6 active · 20 ended
Active mandates
Active
Active
Active
Active
Ended mandates
At this address
Other companies at this address
| Company | CBE no. |
|---|---|
BioLyo Technologies● Active | 0741.579.648 |
ExeVir Bio● Active | 0750.495.334 |
Flindr Labs● Active | 1014.117.578 |
Protealis● Active | 0765.251.410 |
| 0873.953.667 | |
Zomagen Biosciences Belgium● Active | 0744.519.837 |
Financials
Annual accounts
Full financial information
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Micro model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 27/05/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 20 months |
| Filing date | 17/06/2026 | 03/07/2025 | 11/06/2024 | 31/05/2023 | 09/06/2022 |
| General meeting | 20/05/2026 | 30/06/2025 | 15/05/2024 | 17/05/2023 | 24/05/2022 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
5 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 20/05/2026 | 17/06/2026 | Dutch | |
| Abridged model | 31/12/2024 | 30/06/2025 | 03/07/2025 | Dutch | |
| Abridged model | 31/12/2023 | 15/05/2024 | 11/06/2024 | Dutch | |
| Micro model | 31/12/2022 | 17/05/2023 | 31/05/2023 | Dutch | |
| Abridged model | 31/12/2021 | 24/05/2022 | 09/06/2022 | Dutch |
Valuation
Estimate
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 2,5 M€ and 5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 31/12/2025 · 6 active · 20 ended
Active mandates
Active
Active
Active
Active
Ended mandates
Shareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette
Belgian Official Gazette publications
- Mandates26/06/2026ONTSLAGEN - BENOEMINGEN
- Mandates04/05/2026ONTSLAGEN - BENOEMINGEN
- Capital / shares21/04/2026STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN
- Mandates06/01/2026ONTSLAGEN - BENOEMINGEN
- Mandates28/07/2025STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
- Other22/05/2025DIVERSEN
- Mandates31/05/2024STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
- Mandates30/10/2023ONTSLAGEN - BENOEMINGEN
Source: Belgian Official Gazette
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-5,3 M €↓
- 2024Annual accounts 2024-3,8 M €↓
- 2023Annual accounts 2023-2,6 M €↓
- 2022Annual accounts 2022-1,6 M €↑
- 2021Annual accounts 2021-2,0 M €
- 27/05/2020IncorporationPrivate limited company